Cancer Chemotherapy and Pharmacology

, Volume 14, Issue 3, pp 279–281 | Cite as

Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol

  • B. Steinke
  • F. W. Busch
  • C. Becherer
  • P. Ostendorf
  • H. D. Waller
Short Communication Multiple Myeloma, Chemotherapy


A group of 46 patients with melphalan-resistant multiple myeloma was treated according to the M-2 protocol with melphalan, prednisolone, BCNU, cyclophosphamide, and vincristine. According to the Salmon and Durie classification, four patients had stage II A; 36, stage III A; and six, stage III B disease. Treatment resulted in five patients (11%) entering remission, while 21 (46%) had stable and 20 (43%) had progressive disease. The median survival for all patients was 12.5 months, patients in remission surviving longer (median 46 months) than those with stable disease (median 15.4 months) or progressive disease (median 6.9 months). Compared with other treatment regimens used in melphalan-resistant myeloma, the remission rate is low but the median survival exceeds that reported by most other authors.


Cancer Research Melphalan Cyclophosphamide Median Survival Multiple Myeloma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alberts DS, Sydney SE (1975) Adriamycin (NSC-123127) in the treatment of alkylator resistant multiple myeloma: a pilot study. Cancer Chemother Rep 59:345Google Scholar
  2. 2.
    Alberts DS, Durie BGM, Salmon SE (1976) Doxorubicin/BCNU chemotherapy for multiple myeloma in relapse. Lancet I:926Google Scholar
  3. 3.
    Alberts DS, Durie BGM, Sydney SE (1977) Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. Cancer Chemother Rep 61:381Google Scholar
  4. 4.
    Alexanian R (1980) Treatment of multiple myeloma. Acta Haematol (Basel) 63:237Google Scholar
  5. 5.
    Alexanian R, Bonnet J, Gehan E, Haut A, Hewlett J, Lane M, Monto R, Wilson H (1972) Combination chemotherapy for multiple myeloma. Cancer 30:382Google Scholar
  6. 6.
    Alexanian R, Yap BS, Bodey GP (1983) Prednisone pulse therapy for refractory myeloma. Blood 62:572Google Scholar
  7. 7.
    Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB (1979) The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 301:743Google Scholar
  8. 8.
    Blade J, Feliu E, Rozman C, Estape J, Milla A, Monserrat E (1983) Cross-resistance to alkylating agents in multiple myeloma. Cancer 52:786Google Scholar
  9. 9.
    Bonnet J, Alexanian R, Salmon S, Bottomley R, Amare M, Haut A, Dixon D (1982) Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: A Southwest Oncology Group study. Cancer Treat Rep 66:1267Google Scholar
  10. 10.
    Buonanno G, Tortarolo M, Valente A, Castaldo C, Russolillo S, Gonella F (1978) Drug-resistant multiple myeloma. A trial with the M-2-cyclic alkylating agent polychemotherapy. Haematologica (Pavia) 63:5Google Scholar
  11. 11.
    Case DC, Lee BJ, Clarkson BD (1977) Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2-protocol. Am J Med 63:897Google Scholar
  12. 12.
    Durie BG, Salmon SE (1975) A clinical staging system for multiple mycloma. Cancer 36:842Google Scholar
  13. 13.
    Duric BM, Salmon SE (1982) The current status and future prospects of treatment for multiple myeloma. Clin Haematol 11:111Google Scholar
  14. 14.
    Kyle RA, Gailani S, Seligman BR, Blom J, McIntyre OR, Pajak TE, Holland JF (1979) Multiple myeloma resistant to melphalan: Treatment with cyclophosphamide, prednisone and BCNU. Cancer Treat Rep 63:1265Google Scholar
  15. 15.
    Kyle RA, Pajak TF, Henderson ES, Nawabi IU, Brunner K, Henry PH, McIntyre OR, Holland JF (1982) Multiple myeloma resistant to melphalan: Treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisolone. Cancer Treat Rep 66:451Google Scholar
  16. 16.
    Paredes JM, Mitchell BS (1980) Multiple myeloma. Current concepts in diagnosis and management. Med Clin North Am 64:729Google Scholar
  17. 17.
    Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PB (1977) Design and analysis of clinical trials. Br J Cancer 35:1Google Scholar
  18. 18.
    Woodruff R (1981) Treatment of multiple myeloma. Cancer Treat Rep 81:225Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • B. Steinke
    • 1
  • F. W. Busch
    • 1
  • C. Becherer
    • 1
  • P. Ostendorf
    • 1
  • H. D. Waller
    • 1
  1. 1.Clinic of Internal Medicine IIUniversity of TübingenTübingenGermany

Personalised recommendations